VANCOUVER, July 4, 2018 /CNW/ - INVICTUS MD STRATEGIES
CORP. ("Invictus" or the "Company") (TSXV: GENE; OTC: IVITF; FRA:
8IS1) is pleased to announce that for the current fiscal year,
which commenced on February 1, 2018,
the Company has received $5,777,267
from the exercise of previously issued warrants and options. A
total of 4,346,731 warrants and 337,500 options were exercised for
proceeds of $5,267,467 and
$509,800, respectively. As a result
of such exercises, the Company currently has a total of 96,623,857
common shares issued and outstanding.
Invictus expects to use these proceeds to help fund its ongoing
construction program and overall operations. The Company
anticipates a total cannabis cultivation footprint of 262,000
square feet by the end of 2018 and 846,000 square feet by end of
2019. Invictus has approximately 9.9 million warrants and 9.4
million options outstanding that, if exercised, would bring in an
additional $19.7 million and
$14.9 million in cash funds to the
Company.
Invictus has also granted 120,000 incentive stock options to
certain eligible persons of the Company. Each stock option has an
exercise price of $1.50 and is
exercisable into one common share of the Company. The options vest
1/3 in 3 months, 1/3 in nine months, and 1/3 in fifteen months and
are exercisable over a period of five years. The stock options were
granted subject to the terms and conditions of the Company's Stock
Option Plan.
About Invictus
Invictus owns and operates two cannabis production facilities,
both with sales licenses, under the ACMPR in Canada, with the vision of producing a variety
of high quality and low-cost cannabis products to the global
market, as regulations permit. The Company's wholly owned
subsidiary, Acreage Pharms Ltd. ("Acreage Pharms"), is
located in West-Central Alberta. The Company's 50% owned AB
Laboratories Inc. ("AB Labs"), is located in Hamilton, Ontario. AB Ventures Inc. ("AB
Ventures") owns 100 acres of land near Hamilton, Ontario, to be used for future
cannabis cultivation. Recently, the Company announced that it has
entered into a binding letter of intent for an option to acquire an
applicant (the "OptionCo") under the ACMPR. Combined, the
Company expects to have approximately 262,000 and 846,000 square
feet of cannabis production capacity by the end of 2018 and 2019,
respectively.
Gene Simmons, music legend and
media mogul, conveys the vision of Invictus as the Chief Evangelist
Officer.
The Company's wholly owned subsidiary, Poda Technologies Ltd.
("Poda"), has developed the world's first zero-cleaning
vaporizer system. Poda's fully biodegradable pods are
self-contained, and do not contaminate the vaporizer with odor,
flavor or residue.
Finally, the Company's 82.5% owned Future Harvest Development
Ltd. ("Future Harvest") is a high-quality Fertilizer and
Nutrients manufacturer, based in Kelowna, British Columbia. Future Harvest has
been in operation for over 20 years under the brand Plant Life
Products and Holland Secret.
Invictus' Canadian Production Footprint:
|
|
|
Square
Footage
|
Company
|
Phase
|
Province
|
Current
|
31-Dec-18
|
31-Dec-19
|
Acreage
Pharms
|
1
|
Alberta
|
7,000
|
7,000
|
7,000
|
Acreage
Pharms
|
2
|
Alberta
|
33,000
|
33,000
|
33,000
|
Acreage
Pharms
|
3
|
Alberta
|
|
90,000
|
90,000
|
Acreage
Pharms
|
4
|
Alberta
|
|
|
250,000
|
Total Acreage
Pharms
|
|
|
40,000
|
130,000
|
380,000
|
AB Labs
|
1
|
Ontario
|
16,000
|
16,000
|
16,000
|
AB Labs
|
2
|
Ontario
|
|
40,000
|
40,000
|
Total AB
Labs
|
|
|
16,000
|
56,000
|
56,000
|
AB
Ventures
|
1
|
Ontario
|
|
21,000
|
21,000
|
AB
Ventures
|
2
|
Ontario
|
|
|
84,000
|
Total AB
Ventures
|
|
|
|
21,000
|
105,000
|
OptionCo
|
1
|
British
Columbia
|
|
55,000
|
55,000
|
OptionCo
|
2
|
British
Columbia
|
|
|
250,000
|
Total
OptionCo
|
|
|
|
55,000
|
305,000
|
Total
Combined
|
|
|
56,000
|
262,000
|
846,000
|
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
Dan Kriznic
Chairman and CEO
Jessica Martin
Vice President, Public Relations and Regulatory Affairs
(604) 537-8676
Cautionary Note Regarding Forward-Looking Statements: This
release includes certain statements and information that may
constitute forward-looking information within the meaning of
applicable Canadian securities laws or forward-looking statements
within the meaning of the United States Private Securities
Litigation Reform Act of 1995. All statements in this news release,
other than statements of historical facts, including statements
regarding future estimates, plans, objectives, timing, assumptions
or expectations of future performance, including the expected use
of the proceeds from the Company's option and warrant exercises and
the potential production capacity of OptionCo, AB Labs, AB Ventures
and Acreage Pharms, are forward-looking statements and contain
forward-looking information. Generally, forward-looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should" or "would" occur.
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including that there will be no material change in the Company's
business or market conditions that will require the Company to
alter its current anticipated use of the proceeds from the option
and warrant exercises that OptionCo, AB Labs, AB Ventures and
Acreage Pharms will be successful in reaching their potential
production capacity, OptionCo, AB Labs, AB Ventures and Acreage
Pharms' production facilities will be completed as anticipated,
regulatory approval will be granted as anticipated, OptionCo, AB
Labs, AB Ventures and Acreage Pharms will reach full production
capacity on the timeline anticipated by the Company,. These
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
Important factors that may cause actual results to vary, include,
without limitation, there will be a material change in the
Company's business or market conditions that will require the
Company to alter its current anticipated use of the proceeds from
the option and warrant exercises OptionCo, AB Labs, AB Ventures and
Acreage Pharms will not be successful in reaching its potential
production capacity, OptionCo, AB Labs, AB Ventures and Acreage
Pharms production facilities will not be completed as anticipated,
construction delays, regulatory approval will not be granted as
anticipated and therefore, the anticipated timing of OptionCo, AB
Labs, AB Ventures and Acreage Pharms reaching full production
capacity will be delayed. Although management of the Company
has attempted to identify important factors that could cause actual
results to differ materially from those contained in
forward-looking statements or forward-looking information, there
may be other factors that cause results not to be as anticipated,
estimated or intended. There can be no assurance that such
statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
forward-looking statements and forward-looking information. Readers
are cautioned that reliance on such information may not be
appropriate for other purposes. The Company does not undertake to
update any forward-looking statement, forward-looking information
or financial out-look that are incorporated by reference herein,
except in accordance with applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original
content:http://www.prnewswire.com/news-releases/invictus-receives-5-8-million-from-warrant-and-option-exercises-and-issues-incentive-stock-options-300676215.html
SOURCE Invictus MD Strategies